間質性肺疾患の世界市場レポート 2025年

間質性肺疾患市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.9％で28億5,000万米ドルに成長します。予測期間の成長は、精密医療、新薬開発、再生医療、遠隔医療、遠隔モニタリングに起因しています。予測期間における主な動向には、画像技術の進歩、画像診断におけるai、線維症サブタイプの鑑別、支持療法サービスが含まれます。

アレルギー疾患の有病率の増加は、今後の間質性肺疾患（ILD）市場の成長を牽引すると予想されます。アレルギー疾患は、通常は無害なアレルゲンとして知られる物質に対して免疫系が過剰に反応することで発生します。このようなアレルギー反応はILD、特に過敏性肺炎につながる可能性があり、アレルギー反応が肺に炎症を引き起こします。例えば、2023年11月、オーストラリアを拠点とする喘息ケアに特化した組織であるNational Asthma Councilは、2022年の喘息関連死亡者数を467人と報告し、その内訳は女性299人、男性168人でした。これは2021年の死亡者数355人からの増加です。アレルギー性疾患の増加が間質性肺疾患市場の成長に寄与しています。したがって、アレルギー疾患の有病率の増加がILD市場の拡大を加速させています。

自己免疫疾患の罹患率の上昇は、今後数年間の間質性肺疾患市場の成長を促進すると予測されています。自己免疫疾患は、免疫系が誤って身体の健康な組織や細胞を攻撃することで発生します。自己免疫疾患の増加は、ILD関連ヘルスケアサービスの需要を押し上げ、研究開発を促進し、治療と患者ケアの改善を促進することで、ILD市場の成長に寄与しています。例えば、2023年9月、米国を拠点とする世界の健康調査機関であるInstitute for Health Metrics and Evaluationは、2050年までに関節リウマチの世界患者数が3,170万人に達すると予測し、この期間の大幅な増加を反映しています。その結果、自己免疫疾患の罹患率の増加が間質性肺疾患市場の成長を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界間質性肺疾患PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の間質性肺疾患市場：成長率分析
• 世界の間質性肺疾患市場の実績：規模と成長, 2019-2024
• 世界の間質性肺疾患市場の予測：規模と成長, 2024-2029, 2034F
• 世界間質性肺疾患総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の間質性肺疾患市場薬の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口コルチコステロイド
• 免疫抑制
• 抗線維化薬
• その他の薬物
• 世界の間質性肺疾患市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 間質性肺炎
• 特発性肺線維症
• 非特異性間質性肺炎
• 過敏性肺炎
• 特発性器質化肺炎（COP）
• サルコイドーシス
• 急性間質性肺炎
• 世界の間質性肺疾患市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 大人
• 子供たち
• 世界の間質性肺疾患市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の間質性肺疾患市場経口コルチコステロイドの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プレドニゾン
• メチルプレドニゾロン
• デキサメタゾン
• 世界の間質性肺疾患市場、免疫抑制のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アザチオプリン
• メトトレキサート
• ミコフェノール酸モフェチル
• 世界の間質性肺疾患市場抗線維化薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ピルフェニドン
• ニンテダニブ
• 世界の間質性肺疾患市場、その他の医薬品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗酸化物質
• 抗凝固剤
• その他の新しい治療法

第7章 地域別・国別分析

• 世界の間質性肺疾患市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の間質性肺疾患市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 間質性肺疾患市場：競合情勢
• 間質性肺疾患市場：企業プロファイル
  • Roche Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis Pharmaceuticals Corporation Overview, Products and Services, Strategy and Financial Analysis
  • The Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Amgen Inc.
• Boehringer Ingelheim
• Siemens Healthineers
• Koninklijke Philips N.V.
• Teva Pharmaceuticals USA Inc.
• AstraZeneca plc
• Horizon Pharma USA Inc.
• Genentech Inc.
• Amneal Pharmaceuticals LLC
• Fujirebio Diagnostics Inc.
• Insmed Inc.
• VIDA Diagnostics Inc.
• EmphyCorp Inc.
• Verseau Therapeutics
• Regend Therapeutics Co.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 間質性肺疾患市場2029：新たな機会を提供する国
• 間質性肺疾患市場2029：新たな機会を提供するセグメント
• 間質性肺疾患市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Interstitial lung disease (ILD) refers to a group of lung conditions that affect the interstitium, the tissue and space surrounding the alveoli in the lungs. The interstitium is crucial for maintaining the structural integrity and function of the lungs, facilitating the exchange of gases between the lungs and the bloodstream.

The primary types of drugs used in the treatment of interstitial lung disease include oral corticosteroids, immunosuppressive medications, anti-fibrotic drugs, and others. Interstitial pneumonia, also referred to as non-infectious interstitial pneumonia, is a specific type of interstitial lung disease (ILD) that affects the interstitium, the tissue supporting the air sacs (alveoli) in the lungs. These drugs are indicated for the treatment of various ILD conditions, including interstitial pneumonia, idiopathic pulmonary fibrosis, nonspecific interstitial pneumonitis, hypersensitivity pneumonitis, cryptogenic organizing pneumonia (COP), sarcoidosis, and acute interstitial pneumonitis in both adults and children. They are distributed through a range of channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The interstitial lung disease market research report is one of a series of new reports from The Business Research Company that provides interstitial lung disease market statistics, including interstitial lung disease industry global market size, regional shares, competitors with an interstitial lung disease market share, detailed interstitial lung disease market segments, market trends and opportunities and any further data you may need to thrive in the interstitial lung disease industry. This interstitial lung disease market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The interstitial lung disease market size has grown strongly in recent years. It will grow from $1.97 billion in 2024 to $2.11 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to awareness and diagnosis improvement, immune system modulation therapies, respiratory rehabilitation programs, multidisciplinary care teams.

The interstitial lung disease market size is expected to see strong growth in the next few years. It will grow to $2.85 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to precision medicine, novel drug development, regenerative medicine, telehealth and remote monitoring. Major trends in the forecast period include advancements in imaging technology, ai in imaging, fibrosis subtype differentiation, supportive care services.

The increasing prevalence of allergic conditions is expected to drive the growth of the interstitial lung disease (ILD) market in the future. An allergic condition occurs when the immune system overreacts to a substance, known as an allergen, that is typically harmless. Such allergic reactions can lead to ILD, specifically hypersensitivity pneumonitis, where an allergic response causes inflammation in the lungs. For example, in November 2023, the National Asthma Council, an Australia-based organization focused on asthma care, reported 467 asthma-related deaths in 2022, which included 299 females and 168 males. This represents an increase from 355 deaths in 2021. The rise in allergic diseases is contributing to the growth of the interstitial lung disease market. Therefore, the growing prevalence of allergic conditions is accelerating the expansion of the ILD market.

The rising incidence of autoimmune disorders is anticipated to fuel the growth of the interstitial lung disease market in the coming years. Autoimmune disorders occur when the immune system mistakenly attacks the body's healthy tissues and cells. The increasing number of autoimmune conditions is contributing to the growth of the ILD market by boosting demand for ILD-related healthcare services, advancing research and development, and driving improvements in treatments and patient care. For example, in September 2023, the Institute for Health Metrics and Evaluation, a US-based global health research organization, projected that global cases of rheumatoid arthritis will rise to 31.7 million by 2050, reflecting a significant increase over this period. As a result, the rising incidence of autoimmune diseases is propelling the growth of the interstitial lung disease market.

Leading companies in the interstitial lung disease market are focusing on trends such as the introduction of innovative therapies for various conditions, including idiopathic pulmonary fibrosis (IPF). IPF is a chronic and progressive lung disease characterized by the scarring of lung tissue, which results in breathing difficulties and decreased oxygen exchange. For example, in February 2024, C.H. Boehringer Sohn AG & Co. KG, a biopharmaceutical company based in Germany, received FDA approval for its BI 1015550 therapy for the treatment of IPF. BI 1015550 is an investigational oral medication that targets and inhibits phosphodiesterase 4B (PDE4B), providing antifibrotic and anti-inflammatory effects designed to slow the decline in lung function in patients with IPF.

In June 2023, Merck & Co., a US-based pharmaceutical company, acquired Prometheus Biosciences Inc. for $10.3 billion. This strategic acquisition is aimed at strengthening Merck & Co.'s immunology drug pipeline as it faces the looming loss of exclusivity for some of its top-selling products in the coming years. Prometheus Biosciences Inc., a US-based biotechnology company, specializes in developing therapeutic and complementary diagnostic products for the management of immune-mediated disorders, including interstitial lung disease (ILD) associated with systemic sclerosis (SSc-ILD).

Major companies operating in the interstitial lung disease market are Roche Laboratories Inc., Merck & Co. Inc., Bayer AG, Novartis Pharmaceuticals Corporation, The Bristol-Myers Squibb Company, Amgen Inc., Boehringer Ingelheim, Siemens Healthineers, Koninklijke Philips N.V., Teva Pharmaceuticals USA Inc., AstraZeneca PLC, Horizon Pharma USA Inc., Genentech Inc., Amneal Pharmaceuticals LLC, Fujirebio Diagnostics Inc., Insmed Inc., VIDA Diagnostics Inc., EmphyCorp Inc., Verseau Therapeutics, Regend Therapeutics Co., LTT Bio-Pharma Co. Ltd., Galecto Biotech, Pulmatrix Inc., PureTech Health PLC, Pneuma Respiratory Inc., Bellerophon Therapeutics Inc., MediciNova Inc., Altavant Sciences Inc., Verona Pharma plc.

North America was the largest region in the interstitial lung disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in interstitial lung disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the interstitial lung disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The interstitial lung disease market consists of revenues earned by entities by providing services such as individualized treatment plans and comprehensive support, pulmonary rehabilitation and oxygen therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The interstitial lung disease market also includes sales of prednisone, mycophenolate, azathioprine and cyclophosphamide. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Interstitial Lung Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on interstitial lung disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for interstitial lung disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The interstitial lung disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Oral Corticosteroids; Immune Suppressing; Anti-Fibrotic Medication; Other Drugs
• 2) By Disease Type: Interstitial Pneumonia; Idiopathic Pulmonary Fibrosis; Nonspecific Interstitial Pneumonitis; Hypersensitivity Pneumonitis; Cryptogenic Organizing Pneumonia (COP); Sarcoidosis; Acute Interstitial Pneumonitis
• 3) By Application: Adults; Children
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Oral Corticosteroids: Prednisone; Methylprednisolone; Dexamethasone
• 2) By Immune Suppressing: Azathioprine; Methotrexate; Mycophenolate Mofetil
• 3) By Anti-Fibrotic Medication: Pirfenidone; Nintedanib
• 4) By Other Drugs: Antioxidants; Anticoagulants; Other Novel Therapies
• Companies Mentioned: Roche Laboratories Inc.; Merck & Co. Inc.; Bayer AG; Novartis Pharmaceuticals Corporation; The Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Interstitial Lung Disease Market Characteristics

3. Interstitial Lung Disease Market Trends And Strategies

4. Interstitial Lung Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Interstitial Lung Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Interstitial Lung Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Interstitial Lung Disease Market Growth Rate Analysis
• 5.4. Global Interstitial Lung Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Interstitial Lung Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Interstitial Lung Disease Total Addressable Market (TAM)

6. Interstitial Lung Disease Market Segmentation

• 6.1. Global Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Corticosteroids
• Immune Suppressing
• Anti-Fibrotic Medication
• Other Drugs
• 6.2. Global Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interstitial Pneumonia
• Idiopathic Pulmonary Fibrosis
• Nonspecific Interstitial Pneumonitis
• Hypersensitivity Pneumonitis
• Cryptogenic Organizing Pneumonia (COP)
• Sarcoidosis
• Acute Interstitial Pneumonitis
• 6.3. Global Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adults
• Children
• 6.4. Global Interstitial Lung Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Interstitial Lung Disease Market, Sub-Segmentation Of Oral Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prednisone
• Methylprednisolone
• Dexamethasone
• 6.6. Global Interstitial Lung Disease Market, Sub-Segmentation Of Immune Suppressing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Azathioprine
• Methotrexate
• Mycophenolate Mofetil
• 6.7. Global Interstitial Lung Disease Market, Sub-Segmentation Of Anti-Fibrotic Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pirfenidone
• Nintedanib
• 6.8. Global Interstitial Lung Disease Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antioxidants
• Anticoagulants
• Other Novel Therapies

7. Interstitial Lung Disease Market Regional And Country Analysis

• 7.1. Global Interstitial Lung Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Interstitial Lung Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Interstitial Lung Disease Market

• 8.1. Asia-Pacific Interstitial Lung Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Interstitial Lung Disease Market

• 9.1. China Interstitial Lung Disease Market Overview
• 9.2. China Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Interstitial Lung Disease Market

• 10.1. India Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Interstitial Lung Disease Market

• 11.1. Japan Interstitial Lung Disease Market Overview
• 11.2. Japan Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Interstitial Lung Disease Market

• 12.1. Australia Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Interstitial Lung Disease Market

• 13.1. Indonesia Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Interstitial Lung Disease Market

• 14.1. South Korea Interstitial Lung Disease Market Overview
• 14.2. South Korea Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Interstitial Lung Disease Market

• 15.1. Western Europe Interstitial Lung Disease Market Overview
• 15.2. Western Europe Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Interstitial Lung Disease Market

• 16.1. UK Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Interstitial Lung Disease Market

• 17.1. Germany Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Interstitial Lung Disease Market

• 18.1. France Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Interstitial Lung Disease Market

• 19.1. Italy Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Interstitial Lung Disease Market

• 20.1. Spain Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Interstitial Lung Disease Market

• 21.1. Eastern Europe Interstitial Lung Disease Market Overview
• 21.2. Eastern Europe Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Interstitial Lung Disease Market

• 22.1. Russia Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Interstitial Lung Disease Market

• 23.1. North America Interstitial Lung Disease Market Overview
• 23.2. North America Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Interstitial Lung Disease Market

• 24.1. USA Interstitial Lung Disease Market Overview
• 24.2. USA Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Interstitial Lung Disease Market

• 25.1. Canada Interstitial Lung Disease Market Overview
• 25.2. Canada Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Interstitial Lung Disease Market

• 26.1. South America Interstitial Lung Disease Market Overview
• 26.2. South America Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Interstitial Lung Disease Market

• 27.1. Brazil Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Interstitial Lung Disease Market

• 28.1. Middle East Interstitial Lung Disease Market Overview
• 28.2. Middle East Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Interstitial Lung Disease Market

• 29.1. Africa Interstitial Lung Disease Market Overview
• 29.2. Africa Interstitial Lung Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Interstitial Lung Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Interstitial Lung Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Interstitial Lung Disease Market Competitive Landscape And Company Profiles

• 30.1. Interstitial Lung Disease Market Competitive Landscape
• 30.2. Interstitial Lung Disease Market Company Profiles
  • 30.2.1. Roche Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis Pharmaceuticals Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. The Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Interstitial Lung Disease Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Boehringer Ingelheim
• 31.3. Siemens Healthineers
• 31.4. Koninklijke Philips N.V.
• 31.5. Teva Pharmaceuticals USA Inc.
• 31.6. AstraZeneca plc
• 31.7. Horizon Pharma USA Inc.
• 31.8. Genentech Inc.
• 31.9. Amneal Pharmaceuticals LLC
• 31.10. Fujirebio Diagnostics Inc.
• 31.11. Insmed Inc.
• 31.12. VIDA Diagnostics Inc.
• 31.13. EmphyCorp Inc.
• 31.14. Verseau Therapeutics
• 31.15. Regend Therapeutics Co.

32. Global Interstitial Lung Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Interstitial Lung Disease Market

34. Recent Developments In The Interstitial Lung Disease Market

35. Interstitial Lung Disease Market High Potential Countries, Segments and Strategies

• 35.1 Interstitial Lung Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Interstitial Lung Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Interstitial Lung Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer